FDMT - 4D Molecular downgraded at BMO on limited population for wet AMD candidate
2025-01-13 09:26:25 ET
More on 4D Molecular Therapeutics
- 4D Molecular, FDA agree on phase 3 design for DME candidate
- 4D Molecular initiated by Morgan Stanley at underweight
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
- Historical earnings data for 4D Molecular Therapeutics
- Financial information for 4D Molecular Therapeutics